Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

Comprehensive Stroke Center

Highly-Specialized Stroke Care

A stroke is a medical crisis that demands urgency, ideally in the form of ambulance transportation to the emergency room. When a blood vessel is blocked or ruptures, lack of oxygen causes brain cells to die. Immediate, skilled care is vital.

Our stroke center is certified and designated an Advanced Comprehensive Stroke Center by The Joint Commission. Certification as a Comprehensive Stroke Center means that the organization has met The Joint Commission’s standards for Disease-Specific Care Comprehensive Stroke Center Certification, making it part of an elite group of providers focused on complex stroke care. Complex Stroke Centers are recognized as industry leaders and are responsible for setting the national agenda in highly-specialized stroke care. These centers have advanced infrastructure, staff, and training to receive and treat patients with the most complex strokes.

In addition, the center has been honored by the American Heart Association and the American Stroke Association with several awards, including the Gold Quality Award and Get with the Guidelines. We are especially proud of our Target Stroke Award, which recognizes our ability to provide rapid, emergent treatment. Our stroke center is the only recipient of this award in metropolitan Washington.

The hallmark of our stroke care is consistency. The emergency room neurologist follows patients for the duration of their hospital stays and after discharge.

Joint Commission seal with American Heart Association seal for comprehensive stroke center

Conveniently Located

Clinical Trials

  • Phase 3 ALS study (CY 5031) with reldesemtiv. (Cytokinetics)
    This is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS
  • Food as Medicine to Improve Lifestyle for Stroke Patients (FAMILY (CAFB))
    The purpose of this study is to evaluate if groceries delivered every two weeks, along with nutrition education and nutrition counseling, will improve the health of individuals who have recently had a stroke.
  • Sleep for Stroke Management And Recovery Trial (SleepSmart)
    Investigator-initiated, phase 3 multicenter, prospective randomized open-, blinded-endpoint (PROBE) controlled trial to test whether treatment of obstructive sleep apnea (OSA) with continuous positive airway pressure is effective for secondary prevention and recovery after stroke.
  • Preventative treatment of migraine: Outcomes for patients in realy-world healthcare systems (Triumph)
    This study is a 24-month prospective, multicenter, international, 2-stage noninterventional study reflecting treatment within real-world settings of patients with migraine who are switching or initiating pharmacologic treatment for migraine prevention
  • A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice (TV48125)
    A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice
  • A 12 month prospective, randomized, interventional, global, multicenter, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs oral prophylactics) in adult episodic migraine patients (AMG334A2401)
    This study uses a single-cohort, 2-treatment arm (erenumab versus oral SoC prophylactic treatment), parallel-group randomized (2:1 [erenumab (70mg or 140mg): SoC oral prophylactic]), open-label design in adult patients with episodic migraine who have previously failed 1 or 2 prophylactic migraine treatments.
  • A phase 4, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of erenumab in adults with chronic migraine and medication overuse headache (Amgen20170703)
    Study 20170703 is a phase 4, randomized, double-blind, double-dummy, parallel-group, placebo-controlled study to evaluate the safety and efficacy of erenumab against placebo in a CM population with MOH and prior history of treatment failure.
  • A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety and tolerability of atogepant for the prevention of chronic migraine (Allergan3101-303-002)
    Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and tolerability of atogepant 30 mg twice per day (BID) and 60 mg once daily for the prevention of chronic migraine (CM).
  • A phase 2, randomized, placebo-controlled study to evaluate the safety, tolerability and efficacy of TAK-079 in patients with generalized myasthenia gravis (TAK079-1005)
    This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of TAK-079 in patients with generalized MG in combination with standard background therapy.
  • A phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis (UCB MG0003)
    This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 3-arm, repeat dose study evaluating the efficacy and safety of two doses of rozanolixizumab and matching placebo in patients with generalized MG who experience moderate to severe symptoms (Myasthenia Gravis Foundation of America [MGFA II-IVa]) and are being considered for additional treatment such as IVIg or PEX
  • A phase II study to evaluate the safety and tolerability of pyridostigmine when given with ondansetron to subjets with anti-AChR postive myasthenia gravis (DAS-MG)
    This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis to compare the gastrointestinal (GI) side effects of pyridostigmine alone and when given with ondansetron in patients with a known diagnosis of anti-AchR antibody positive myasthenia gravis and current (i.e., past 7 days) pyridostigmine-related GI side effects
  • A phase 3, multicenter, open-label extension study of Zilucoplan in subjects with generalized myasthenia gravis (RA Pharma 302: Raise XT)
    Study RA101495-02.302 is a multicenter, open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study. The visit schedule during the first 12 weeks of Study RA101495-02.302 (RAISE)